Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL) Producing and AmpC Hyperproducing Enterobacteriaceae in United Kingdom.

Trial Profile

Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL) Producing and AmpC Hyperproducing Enterobacteriaceae in United Kingdom.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2013

At a glance

  • Drugs Temocillin (Primary)
  • Indications Enterobacteriaceae infections; Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TEA
  • Sponsors Belpharma
  • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Eumedica added as associations as reported in the European Clinical Trials Database record.
    • 02 Mar 2012 Additional lead trial investigator (Peter M Hawkey) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top